Skip to main content

Allogeneic and Autologous Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia in the Adult

  • Chapter
Book cover Hematopoietic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

Keywords

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995;85:1151–1168.

    PubMed  CAS  Google Scholar 

  2. Hoelzer D, Ludwig WD, Thiel D, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996;87:495–508.

    PubMed  CAS  Google Scholar 

  3. Hoelzer D, Thiel E, Loffler T, et al. Prognostic factors in a multricentric study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123–131.

    PubMed  CAS  Google Scholar 

  4. Laport GF, Larson RA. Treatment of adult acute lymphoblastic leukemia. Semin Oncol 1997;24:70–82.

    PubMed  CAS  Google Scholar 

  5. Faderl S, Kantarjian M, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998;91:3996–4019.

    Google Scholar 

  6. Hoelzer D, Goekbuget N, Ottmann OG. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Semin Hematol 2002;39:32–37.

    Article  PubMed  CAS  Google Scholar 

  7. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396–4407.

    Article  PubMed  CAS  Google Scholar 

  8. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006;108:1469–1477.

    Article  PubMed  CAS  Google Scholar 

  9. Linker CA, Leavitt LJ, O'Donnell M, et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991;78:2814–2822.

    PubMed  CAS  Google Scholar 

  10. Larson RA, Dodge RK, Burns PC, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995;85:2025–2037.

    PubMed  CAS  Google Scholar 

  11. Hoelzer D, Thiel H, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymhoblastic leukemia in adults. Blood 1988;71:123–131.

    PubMed  CAS  Google Scholar 

  12. Kantarjian HM, O'Brien S, Smith TL, et al: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphoblastic leukemia. J Clin Oncol 2000;18:547–561.

    PubMed  CAS  Google Scholar 

  13. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lym-phoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760–3767.

    Article  PubMed  CAS  Google Scholar 

  14. Thomas X, Boiron J-M, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial. J Clin Oncol 2004;22:4075–4086.

    Article  PubMed  CAS  Google Scholar 

  15. Gokbuget N., Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematology 2006;133–141.

    Google Scholar 

  16. Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium protocols. J Clin Oncol 2007;25:813–819.

    Article  PubMed  CAS  Google Scholar 

  17. Cave H, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1998;339:591–598.

    Article  PubMed  CAS  Google Scholar 

  18. Rovera G, Wasserman R, Yamada, M. Detection of minimal residual disease in childhood leukemia with the polymerase reaction. N Engl J Med 1991;324:774–781.

    Google Scholar 

  19. Mortuza FY, Papaioannou M, Moreira IM, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002;20:1094–1104.

    Article  PubMed  Google Scholar 

  20. Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006;107:1116–1123.

    Article  PubMed  Google Scholar 

  21. Forman SJ. Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation, 3rd ed. Malden, MA: Blackwell Publishing, Inc., 2004:1055–1066.

    Google Scholar 

  22. Marks DI, Forman SJ, Blume KG, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 2006;12:438–453.

    Article  PubMed  CAS  Google Scholar 

  23. Jamieson CH, Amylon MD, Wong RM, Blume KG. Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: a 15-year experience. Exp Hematol 2003;31:981–986.

    Article  PubMed  Google Scholar 

  24. Rowe JM, Buck G, Fielding A, et al. In adults with standard-risk acute lym-phoblastic leukemia (ALL) the greatest benefit is achieved from an allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy: Final results of the international ALL trial (MRC UKALL XII/ECOG E2993). Blood 2006;108:5a.

    Article  Google Scholar 

  25. Snyder D, Nademanee A, O'Donnell MR et al: Allogeneic bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in first complete remission: long term followup. Blood 1998;92:657a.

    Google Scholar 

  26. Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005;105:3449–3457.

    Article  PubMed  CAS  Google Scholar 

  27. Radich J, et al. Detection of bcr-abl transcripts in Philadelphia chromosome positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997;89:2602–2609.

    PubMed  CAS  Google Scholar 

  28. Carpenter PA, Snyder DS, Flowers ME. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007;109:2791–2793.

    PubMed  CAS  Google Scholar 

  29. Giona F, Testi A, Amadori G, et al. Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. Ann Oncol 1990;1:51–55.

    PubMed  CAS  Google Scholar 

  30. Hiddemann W, Kreutzman H, Straif K, et al: High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid leukemia and lymphoblastic leukemia. Semin Oncol. 1987;14:73–77.

    PubMed  CAS  Google Scholar 

  31. Kantarjian HM, Walters RL, Keating MJ et al: Mitoxantrone and high-dose cyto-sine arabinoside for the treatment of refractory acute lymphoblastic leukemia. Cancer 1990;65:5–8.

    Article  PubMed  CAS  Google Scholar 

  32. Weiss MA. Treatment of adult patients with relapsed or refractory acute lymphob-lastic leukemia (ALL). Leukemia. 1997;11:S28–S30.

    PubMed  Google Scholar 

  33. Doney K, Hagglund H, Leisenring W, Chauncey T, Appelbaum FR, Storb R. Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2003;9:472–481.

    Article  PubMed  Google Scholar 

  34. Saarinen-Pihkala UM, Gustafsson G, Ringden O, et al: No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 2001;19:3406–3414.

    PubMed  CAS  Google Scholar 

  35. Kollman C, Howe CW, Anasetti C, et al: Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: The effect of donor age. Blood 2001;98:2043–2051.

    Article  PubMed  CAS  Google Scholar 

  36. Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004;22:2816–2825.

    Article  PubMed  Google Scholar 

  37. Dahlke J, Kroger N, Zabelina T, et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant 2006;37:155–163.

    Article  PubMed  CAS  Google Scholar 

  38. Kanamori H; Sasaki S; Yamazaki E et al: Eradication of minimal residual disease during graft-versus-host reaction induced by abrupt discontinuation of immunosup-pression following bone marrow transplantation in a patient with Ph1-ALL. Transpl Int 1997;10:328–330.

    PubMed  CAS  Google Scholar 

  39. Valcarcel D, Martino R, Sureda A, et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hema-tological malignancies. Eur J Haematol 2005;74:144–151.

    Article  PubMed  CAS  Google Scholar 

  40. Stein A, O'Donnell M, Snyder D, et al. Reduced-intensity stem cell transplantation for high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transpl 2007;13:134.

    Article  Google Scholar 

  41. Gorin NC. Autologous stem cell transplantation in acute lymphocytic leukemia. Stem Cells 2002;20:3–10.

    Article  PubMed  CAS  Google Scholar 

  42. Fiere D, Lepage E, Sebban C, et al: Adult acute lymphoblastic leukemia: a mul-ticentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 1993;11:1990–2001.

    PubMed  CAS  Google Scholar 

  43. Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995;86:1619–1628.

    PubMed  CAS  Google Scholar 

  44. Stockerl-Goldstein KE, Blume KG. Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation, 3rd ed. Malden, MA: Blackwell Publishing, Inc., 2004:1025–1039.

    Google Scholar 

  45. Lowenberg B, Downing J, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051–1062.

    Article  PubMed  CAS  Google Scholar 

  46. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class pr gene expression monitoring. Science 1999;286:531–537.

    Article  PubMed  CAS  Google Scholar 

  47. Yunis JJ, Brunning RD, Howe RB, Lobell M. High-resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukemia. N Engl J Med 1984;311:812–818.

    Article  PubMed  CAS  Google Scholar 

  48. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325–4336.

    Article  PubMed  CAS  Google Scholar 

  49. Sanz MA. Treatment of acute promyelocytic leukemia. Hematology 2006;147–155.

    Google Scholar 

  50. Beaumont M, Sanz M, Carli PM, et al. Therapy related acute promyelocytic leukemia. A report on 106 cases. J Clin Oncol 2003;21:2123–2137.

    Article  PubMed  CAS  Google Scholar 

  51. Marcucci G, Mrozek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005;23:5705–5717.

    Article  PubMed  Google Scholar 

  52. Stein AS, Slovak ML, Sniecinski I, et al. Immunotherapy with IL-2 after autolo-gous stem cell transplant for acute myelogenous leukemia in first remission. Proceedings of the Ninth International Symposium on Autologous Blood and Marrow Transplantation 1999;1:46–53.

    Google Scholar 

  53. Saunders MJ, Tobal K, Liu Yin JA. Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation. Leuk Res 1994;18:891–895.

    Article  PubMed  CAS  Google Scholar 

  54. Nucifora G, Larson RA, Rowley RD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long term remission. Blood 1993;82:712–715.

    PubMed  CAS  Google Scholar 

  55. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107:1791–1799.

    Article  PubMed  CAS  Google Scholar 

  56. Marcucci G, Mrozek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005;23:5705–5717.

    Article  PubMed  Google Scholar 

  57. Rege K, Swansbury GJ, Atra AA, et al. Disease features in acute myeloid leukemia with t(8;21) (q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leukemia & Lymphoma 2000;40:67–77.

    Article  CAS  Google Scholar 

  58. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission. Results of MRC AML 10 trial. Lancet 1998;351:700–708.

    Article  PubMed  CAS  Google Scholar 

  59. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995;332:217–223.

    Article  PubMed  CAS  Google Scholar 

  60. Bienz M, Ludwig M, Mueller BU, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005;11:1416–1424.

    Article  PubMed  CAS  Google Scholar 

  61. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011–4020.

    Article  PubMed  CAS  Google Scholar 

  62. Bornhäuser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C for the AML SHG 96 study group. Improved outcome after stem-cell transplantation in FLT3/ ITD-positive AML. Blood 2007;109:2264–2265.

    Article  Google Scholar 

  63. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075–4083.

    PubMed  CAS  Google Scholar 

  64. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107:3481–3485.

    Article  PubMed  CAS  Google Scholar 

  65. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94:1086–1099.

    PubMed  CAS  Google Scholar 

  66. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease free survival time in AML, RAEB-t, and RAEB. Blood 2000;95:72–77.

    PubMed  CAS  Google Scholar 

  67. Tallman MS, Rowlings PA, Milone G, et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 2000;96:1254–1258.

    PubMed  CAS  Google Scholar 

  68. Cohen, S. and Forman, S.J. Allogeneic and autologous stem cell transplantation for acute lymphoblastic leukemia, acute myelogenous leukemia and myelodysplasia in the adult. Stem Cell Transplantation for Hematologic Malignancies. Soiffer, R.J., editor. Humana Press, Totowa, NJ, 2004.

    Google Scholar 

  69. Armand P, Kim HT, Deangelo DJ, et al. Impact of cytogenetics of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007;13:655–64.

    Article  PubMed  CAS  Google Scholar 

  70. Kim TH, McGlave PB, Ramsay N, et al. Comparison of two total body irradiation regimens in allogeneic bone marrow transplantation for acute nonlymphoblastic leukemia in first remission. Int J Radiat Oncol Biol Phys 1990;19:889–897.

    Article  PubMed  CAS  Google Scholar 

  71. Popplewell L, Forman SJ. Allogeneic hematopoietic stem cell transplantation for acute leukemia, chronic leukemia, and myelodysplasia. Hematology/Oncology Clinics of North America 1999;13:987–1015.

    Article  PubMed  CAS  Google Scholar 

  72. Andersson BS, Gajewski J, Donato M, et al. Allogeneic stem cell transplantation (BMT) for AML and MDS following IV busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplantation 2000;25:S35–S38.

    Article  PubMed  Google Scholar 

  73. Appelbaum FR. Radioimmunotherapy and hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation, 2nd ed. London: Blackwell Science, Inc., 1999:168–175.

    Google Scholar 

  74. Chantry AD, Snowden JA, Craddock C, et al. Long term outcomes of myeloabla-tion and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study. Biol Blood Marrow Transplant 2006;12:1310–1317.

    Article  PubMed  Google Scholar 

  75. Miller CB, Rowlings PA, Zhang MJ, et al. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol 2001;29:1336–1346.

    Article  PubMed  CAS  Google Scholar 

  76. Forman SJ, Schmidt GM, Nademanee AP, et al: Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol 1991;9:1570–1574.

    PubMed  CAS  Google Scholar 

  77. Mehta J, Powles R, Horton C, et al. Bone marrow transplantation for primary refractory acute leukemia. Bone Marrow Transplant 1994;14:415–418.

    PubMed  CAS  Google Scholar 

  78. Biggs JC, Horowitz MM, Gale RP, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992;80:1090–1093.

    PubMed  CAS  Google Scholar 

  79. Fung HC, O'Donnell M, Popplewell L, et al: Allogeneic stem cell transplantation (SCT) for patients with primary refractory acute myelogenous leukemia (AML): impact of cytogenetic risk group on the transplant outcome. Blood 2001;98:483a.

    Article  Google Scholar 

  80. Tallman MS, Kopecky KJ, Amos D, et al: Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. J Clin Oncol 1989;7:326–337.

    PubMed  CAS  Google Scholar 

  81. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004;104: 865–872.

    Article  PubMed  CAS  Google Scholar 

  82. Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006;20:322–328

    Article  PubMed  CAS  Google Scholar 

  83. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allo-geneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006;20:128–135.

    Article  PubMed  CAS  Google Scholar 

  84. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allo-geneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19:2304–2312.

    Article  PubMed  CAS  Google Scholar 

  85. Martino R, Lacobelli S, Brand R, et al. Retrospective comparison of reduced intensity conditioning and conventional high dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2006;108:836–846.

    Article  PubMed  CAS  Google Scholar 

  86. Stein AS, Forman SJ. Autologous hematopoietic cell transplantation for acute myeloid leukemia. In: Forman SJ, Blume KG, Thomas ED, eds. Hematopoietic Cell Transplantation 2nd ed, London: Blackwell Science Inc., 1999:963–77.

    Google Scholar 

  87. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission. Results of MRC AML 10 trial. Lancet 1998;351:700–8.

    Article  PubMed  CAS  Google Scholar 

  88. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995;332:217–23.

    Article  PubMed  CAS  Google Scholar 

  89. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649–56.

    Article  PubMed  CAS  Google Scholar 

  90. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075–4083.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Anthony, S., Stephen, F.J. (2008). Allogeneic and Autologous Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia in the Adult. In: Soiffer, R.J. (eds) Hematopoietic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-438-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-438-4_4

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-05-3

  • Online ISBN: 978-1-59745-438-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics